ELISA News and Research

RSS

PRISM technique as accurate as ELISAs in identifying proteins within biological samples

Combining two well-established analytic techniques and adding a twist identifies proteins from blood with as much accuracy and sensitivity as the antibody-based tests used clinically, researchers report this week in Proceedings of the National Academy of Sciences Early Edition online.

4 Sep 2012

Passenger deletions that deactivate essential genes provide new opportunity to strike cancer

Genomic deletions promote cancer by carving up or eliminating tumor-suppressor genes, but now scientists report in the journal Nature that the collateral damage they inflict on neighboring genes exposes cancer cells to vulnerabilities and new avenues for attack.

16 Aug 2012

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive clinical results from its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis.

16 Jul 2012

ACLA announces full and strong support for TEST Act

The American Clinical Laboratory Association (ACLA) today announced its "full and strong support" for H.R. 6118, the Taking Essential Steps for Testing Act or TEST Act introduced by Rep. Michael Grimm (R-NY) in the House of Representatives.

16 Jul 2012

ERBA Diagnostics to showcase full range of products at AACC annual meeting

ERBA Diagnostics, Inc., a fully integrated in vitro diagnostics company, is pleased to announce that Suresh Vazirani, Chairman of ERBA Diagnostics, will be a key note speaker at the International Marketing Brief (IMB) in conjunction with the AACC.

16 Jul 2012

FDA approves test for dengue virus infection

The first test that can detect the presence of the dengue virus itself rather than antibodies to the virus has been approved for use by the US Food and Drug Administration.

27 Jun 2012

Scientists develop super-sensitive test that could detect diseases earlier

Scientists have developed an ultra-sensitive test that should enable them to detect signs of a disease in its earliest stages, in research published today in the journal Nature Materials.

28 May 2012

Ultra-sensitive test can diagnose diseases in their earliest stages

Scientists have developed an ultra-sensitive test that should enable them to detect signs of a disease in its earliest stages, in research published today in the journal Nature Materials.

28 May 2012

Aushon plans global launch of new multiplex protein biomarker platform

Aushon announced its plans today for an upcoming global launch of its new multiplex protein biomarker platform, which incorporates several engineering breakthroughs to deliver ELISA-level performance.

21 May 2012

CINJ experts to offer nutrition and cancer prevention tips on Memorial Day weekend

As many prepare to fire up the grill this Memorial Day weekend, experts from The Cancer Institute of New Jersey (CINJ) are offering tips on healthy summer nutrition habits and cooking methods that can be an important part of cancer prevention. CINJ is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School.

16 May 2012

Integral Molecular receives U.S. patent for methodology that generates Lipoparticles

Integral Molecular, a leader in membrane protein reagents and services, announces the issuance of a key patent protecting its methodology for generating Lipoparticles, which provide highly-concentrated membrane proteins in their native conformation for antibody and drug discovery applications focused on membrane protein targets such as G protein-coupled receptors (GPCRs), ion channels, and transporters.

4 May 2012

Seed localization improves satisfaction of breast cancer patients

A cutting-edge procedure called seed localization is improving patient satisfaction at The Dubin Breast Center of the Tisch Cancer Institute at The Mount Sinai Medical Center. In patients undergoing lumpectomy for cancers that are small and cannot be felt in the breast, a tiny radioactive seed is guided into the breast and implanted at the site of the tumor.

2 May 2012

Immunosignatures can yield reliable and highly stable diagnostic results

Identifying diseases at an early, presymptomatic stage may offer the best chance for establishing proper treatment and improving patient outcomes. A new technique known as immunosignaturing harnesses the human immune system as an early warning sentry-one acutely sensitive to changes in the body that may be harbingers of illness.

24 Apr 2012

HSP27 protein can indicate lung damage during early stages of COPD

Chronic obstructive pulmonary disease (COPD) is a widespread disease. In Austria alone, there are between 500,000 and 600,000 sufferers; around ninety per cent of cases are the result of smoking. Now, under the leadership of Hendrik Jan Ankersmit, a research team from the University Department of Surgery at MedUni Vienna and the Christian Doppler Laboratory for the Diagnosis and Regeneration of Heart and Thorax Diseases has discovered a protein marker in the blood that can already indicate lung damage during the early stages of COPD, before a decrease in lung volume is detected by a pulmonary function test.

5 Apr 2012

CINJ experts available to discuss importance of healthy diet and its role in cancer prevention

March is National Nutrition Month. "Get Your Plate in Shape" is the national theme for this year's month-long reminder that good nutrition is essential for your heath. Throughout the month, experts from The Cancer Institute of New Jersey (CINJ) will be available to discuss the importance of a healthy diet and its role in cancer prevention.

27 Feb 2012

China's SFDA approves Dynex DS2 ELISA analyzer

Dynex Technologies announced today it has received approval from China's State Food and Drug Administration (SFDA) to market the DS2 automated enzyme-linked immunosorbent assay (ELISA) analyzer in China.

From Thermo Fisher Scientific Inc. 22 Feb 2012

Elan fourth quarter total revenue increases 18% to $271.0 million

Elan Corporation, plc today reported its fourth quarter and full-year 2011 financial results.

8 Feb 2012

FDA allows marketing of Stratify JCV Antibody ELISA test for PML

Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn's disease.

21 Jan 2012

FDA approves product label change for Biogen Idec's TYSABRI to treat MS

Today Biogen Idec and Elan Corporation, plc announced that the U.S. Food and Drug Administration (FDA) has approved a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis.

21 Jan 2012

NanoInk launches new automated protein NanoArray assay platform

The Nano BioDiscovery™ Division of NanoInk®, Inc. announced today the release of a new automated platform for the analysis of its protein NanoArray assays. NanoInk’s NanoArray Assay System™ enables detection, identification, and quantitation of clinically relevant, low abundance proteins from a wide variety of sample types for applications such as biomarker analysis, translational medicine, and toxicology.

10 Jan 2012